Clinical Research
Filter News
Found 120,839 articles
-
Pfizer is continuing to invest in gene therapy research and development and other areas going on throughout the company, specifically in its North Carolina sites in Chapel Hill and Kit Creek.
-
Clinical Catch-Up: October 12-16
10/19/2020
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look. -
They believe that by inhibiting factor D, it would reduce the inflammatory reactions that make COVID-19 so deadly.
-
Dr. Monica Gandhi, MD, an infectious diseases doctor and professor of medicine at UC San Francisco, poses the hypothesis that masks and other social distancing measures may reduce the viral inoculum – or amount – of the SARS-CoV-2 we contract.
-
Recombinetics Inc. to Partner with American Preclinical Services to Improve Glioblastoma Outcomes
10/19/2020
Recombinetics Inc., a leading gene editing company with platform technology applied to biomedicine and animal agriculture, today announced that it has partnered with American Preclinical Services in a first of its kind study to improve Glioblastoma outcomes.
-
Plexision Awarded Competitive Grant from the National Science Foundation to Develop its Novel COVID-19 Immunity Test
10/19/2020
Plexision, ( www.plexision.com ) a biotech company specializing in cell-based technologies, has been awarded a National Science Foundation (NSF) Phase 1 Small Business Innovation Research grant. This funding will be used to develop a widely available version of Plexision’s novel immunity test for COVID-19 infection. Current tests assess protect
-
Therapeutic Solutions International Reports Positive Preclinical Data on Multiple Sclerosis using NanoStilbene™
10/19/2020
Company Continues on its Mantra of "Science Based" Nutraceutical Development in Expanding Uses of its Patented Nanotechnology based Pterostilbene
-
Thermo Fisher Scientific Increases Availability of COVID-19 Testing with Sample Collection Kit from Everlywell
10/19/2020
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced it has received an expansion of its Emergency Use Authorization (EUA) for the TaqPath COVID-19 Combo Kit to include an additional sample collection method provided by Everlywell, a leading digital health testing company. The TaqPath test is aut
-
FDA Approves New Container System for Peritoneal Dialysis Solutions
10/19/2020
Fresenius Medical Care North America Announces Next Generation Solution Bags to Support Continued Home Dialysis Expansion
-
Inari Medical Announces Presentation of Positive Results from First Patients in Real World FLASH Registry
10/19/2020
- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced positive results of the first 230 patients enrolled in its FLASH study. Interim data of this real world pulmonary embolism (“PE”) population, including high- and intermediate-risk patients, was obtained across 19 US sites. Results were
-
Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s DiseaseMutation Validates Cognition Approach to Oligomer Displacement
10/19/2020
Cognition Therapeutics, Inc. , a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that a peer-reviewed manuscript, entitled, “Icelandic Mutant Human Amyloid-β 1-42 Peptide Forms Fewer Oligomers with Lower Binding Affinity than Wild-Type Peptide,” has been published online in the Journal of Neurochemistry ( doi:10.1111/jnc.15212 ). It has b
-
Cocrystal Pharma Provides Update on Influenza A Program
10/19/2020
– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain – – Company continues to advance IND-enabling studies for Phase 1 clinical study in 2021 –
-
Recce Pharmaceuticals Receives Ethics Approval to Start Phase I/II Study Evaluating Topical Spray-On Synthetic Antibiotic RECCE® 327 on Chronic Burn Wounds
10/19/2020
Highlights : Study will assess safety and efficacy of RECCE ® 327 against a broad range of infectious bacteria on chronic burn wounds in up to 30 patients over two week period Study anticipated to be sponsored by South Metropolitan Health Service , Department of Health, Government of Western Australia (WA) Fiona Stanley Hospital ( B urns U nit) in Perth Western Australia identified as study site SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE)
-
Reflect Scientific Awarded Patent for COVID Vaccine Capable- Self Powered, Low Temperature Controlled Bulk Shipping System
10/19/2020
Reflect Scientific, Inc. (Symbol: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries, announces a recently awarded patent for a cryogenic modular shipping unit that can reliably and uniformly maintain its payload at temperatures as low as -90 degrees Celsius, making it an ideal system for cold chain management of biologics like COVID 19 vaccines. The cryogenic system provides the
-
Solarea Bio Announces Series A Financing Led by S2G Ventures and Bold Capital Partners
10/19/2020
Financing will advance its musculoskeletal product through a clinical proof of activity trial as well as continue the discovery and development of its ongoing pipeline of microbial-based products for human health and well-being.
-
Rafarma Closes Biocogency Merger
10/19/2020
Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that it has closed the merger with BIOCOGENCY LABORATORIES. The new consolidated financials will include Slavich ( http://www.slavich.ru ), Slavich Trading House and related companies based in Spain, Ireland and Cyprus, with Kras Pharma ( http://kraspharma.ru ) and Bebig ( http://en.bebig.ru /) being added in due course. The company’s Slovenian assets will be divested, p
-
BARDA reselects ICON as preferred partner to help strengthen US emergency preparedness and response
10/19/2020
ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries and government and public health organisations, has been re-selected by the Biomedical Advanced Research and Development Authority (BARDA) to c
-
Neurelis Announces FDA Approval Of Extended Expiration Dating For VALTOCO® (Diazepam Nasal Spray)
10/19/2020
Neurelis, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted extended expiration dating for the company's lead product, VALTOCO ® (diazepam nasal spray). VALTOCO was approved by the FDA on January 10, 2020 , for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, s
-
Bio Products Laboratory Receives Triangle Business Journal's Fast 50 Award
10/19/2020
- Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies with US headquarters in Durham, North Carolina , and worldwide headquarters and manufacturing facilities in Elstree, UK, has been reco
-
Sesen Bio Announces an Exclusive Agreement With Cardinal Health for Third-Party Logistics and Specialty Pharmaceutical Distribution Services for Vicineum™
10/19/2020
Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company has selected Cardinal Health as its exclusive provider for third-party logistics (3PL) and specialty pharmaceutical distribution services related to the commercial distribution of Vicineum in the United States (U.S.). The Company’s lead progr